Basel, Switzerland, 2007/03/12
Genedata announces the release of Genedata ToxPedia™, a computational solution supporting organizations to adopt systems toxicology for drug safety prediction. Systems toxicology promises to reduce costly failures in the late stages of drug development and is attracting interest from pharmaceutical companies as well as drug safety regulators.
To gain the greatest benefit from systems toxicology, scientists need to integrate toxicogenomic data with conventional toxicological end points. This integration enables a systematic search for clinically relevant molecular biomarkers that can be used to predict a compound’s toxicity profile, before expensive clinical trials are initiated.
ToxPedia supports a data driven approach to systems toxicology. The system enables biomarker identification based on an integrated analysis of toxicogenomic data, namely of high throughput transcriptomics, proteomics and metabolomics data, with conventional toxicological end points. The ToxPedia system is built on the well established Genedata Expressionist® platform and has been expanded by Genedata’s professional services team in close collaboration with scientists from leading pharmaceutical organizations.
The system is designed to address the specific requirements of systems toxicology. Tight integration with all major high throughput technology platforms, coupled with sophisticated data quality assessment tools, enables ToxPedia to achieve the highest standards in data quality evaluation. Ultimately, the goal is that ToxPedia supports the standardization and automation of the entire systems toxicology workflow from the initial sample gathering stage through to final study reporting phases, and addresses compliancy aims such as 21 CFR Part 11 guidelines.
Genedata also collaborates actively with research consortia focused on biomarker discovery, including the consortia InnoMed, NewGeneris, and INCA. “In collaboration with leading scientists in the pharmaceutical industry as well as in academia, we have developed a state-of-the-art computational system for the emerging field of systems toxicology”, explained Dr. Othmar Pfannes, CEO, Genedata AG. “With ToxPedia, we continue to bring significant value and cost savings to pharmaceutical R&D.”
Contact
Genedata AG
Dr Tobe Freeman
Manager Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
Tobe.Freeman@genedata.com
www.genedata.com
Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com. For more information about ToxPedia, please visit www.genedata.com/solutions.
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Related Files:
PDF version